3D Systems achieves FDA 510(k) clearance for VSP Orthopedics

The US Food and Drug Administration (FDA) has granted 510(k) clearance for 3D Systems’ VSP Orthopedics virtual surgical planning and patient-specific instrumentation platform to include skeletally mature adolescents of normal bone stature, in addition to adults.

Key investment highlights

Immediate commercial acceleration: Eliminates case-by-case compassionate-use approvals and hospital IRB reviews previously required for these adolescent patients, streamlining workflows and converting off-label usage into standard, reimbursable procedures at leading centers.

Targets high-acuity, underserved segment: Over 1,200 new annual US cases of osteosarcoma and Ewing sarcoma in patients under 20 (American Cancer Society, SEER estimates), an additional 2,600 primary bone cancer cases in young adults (20–39) are now fully in scope, and thousands of complex lower-limb osteotomies and reconstructive procedures annually for congenital, developmental, and trauma-related deformities in adolescents.

Strong, sustainable financial model: VSP Orthopedics cases generate service fees for virtual planning combined with revenue from patient-specific 3D printed anatomic models and single-use surgical guides produced on 3D Systems’ additive manufacturing platforms. Resulting revenues contribute to the strong, double-digit annual growth rates and highly accretive gross margins associated with 3D Systems’ Med Tech business.

Strengthened competitive moat: 3D Systems is the only provider with FDA-cleared VSP solutions spanning craniomaxillofacial, orthopedics, and now expanded adolescent applications, with a total of over 400,000 patient-matched cases and devices delivered to date.

Favorable reimbursement: Procedures covered under existing DRG/CPT codes for tumor resection, osteotomy, and reconstruction – no changes required.

“This regulatory clearance removes a significant friction point for adoption in the pediatric/adolescent orthopedic oncology segment. Surgeons at leading centers have been using off-label or compassionate use solutions for years; this decision immediately converts those cases into routine clinical practice and opens the US adolescent bone sarcoma and deformity market to our platform. We are thrilled to now offer these solutions to an expanded and underserved patient population,” said Ben Johnson, Senior Vice President of Medical Technology at 3D Systems.

This regulatory clearance further supports 3D Systems’ focus on high-margin personalized healthcare solutions amid ongoing segment optimization efforts. Continuing expanded indications provide a meaningful tailwind for sustaining double-digit average annual growth in the Healthcare segment, driven in part by accelerated adoption in this discrete, high-value market.